RE-BVS – Piemonte Repository

Sfoglia per AUTORE
DI FIORE P
Collezione ASL Asti

Items : 9

Late response to anti-CGRP (calcitonin gene-related peptide) monoclonal antibodies: implication for clinical practice in European Journal of Neurology

2022
ASL Asti

Aurilia C; Egeo G; Fiorentini G; Cevoli S; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Altamura C; Colombo B; Frediani F; Mercuri B; D'Onofrio F; Grazzi L; Aguggia M; Finocchi C; Di Fiore P; Zucco M; Trimboli M; Bonassi S; Vernieri F; Barbanti P;

Predictors of response to antiCGRP monoclonal antibodies: a multicenter, 24-week, cohort study on 864 migraine patients in European Journal of Neurology

2022
ASL Asti
ASL Vercelli

Egeo G; Aurilia C; Cevoli S; Fiorentini G; Altamura C; Finocchi C; Di Clemente L; Zucco M; Raniero A; Trimboli M; Bono F; Filippi M; Proietti S; Bonassi S; Le Pera D; Albanese M; Grazzi L; Di Fiore P; D'Onofrio F; Aguggia M; Colombo B; Torelli P; Vernieri F; Barbanti P;

Late response to anti-CGRP monoclonal antibodies occurs in one-third of migraine patients in Headache

2022
ASL Asti

Aurilia C; Egeo G; Fiorentini G; Cevoli S; Messina R; Torelli P; Salerno A; Albanese M; Carnevale A; d'Onofrio F; Finocchi C; Altamura C; Aguggia M; Mercuri B; Bono F; Grazzi L; D'Amico D; Filippi M; Colombo B; Frediani F; Favoni V; Di Fiore P; Bertuzzo D; Zucco M; Di Clemente L; Trimboli M; Proietti S; Bonassi S; Vernieri F; et alii...

Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study in European Journal of Neurology

2022
ASL Asti

Vernieri F; Altamura C; Brunelli N; Costa CM; Aurilia C; Egeo G; Fofi L; Favoni V; Lovati C; Bertuzzo D; d’Onofrio F; Doretti A; Di Fiore P; Finocchi C; Schiano Di Cola F; Ranieri A; Colombo B; Bono F; Albanese M; Cevoli S; Barbanti P; Pierangeli G; Capogrosso C; Aguggia M; Spitaleri D; Messina S; Trogu F; Frediani F; Baldi O; et alii...

Long term (48-weeks) effectiveness, safety and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in real-world: The early 2 study in Journal of the Neurological Sciences

2021
ASL Asti

Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F; Colombo B; Frediani F; Mercuri B; D'Onofrio F; Grazzi L; Aguggia M; Favoni V; Finocchi C; Di Fiore P; Costa CM; Brunelli N; Fallacara A; Bertuzzo D; Zucco M; Di Clemente L; et alii...

Long-term (>48 weeks) safety and tolerability of erenumab in reallife in Journal of Headache and Pain

2021
ASL Asti

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study) in Journal of Headache and Pain

2021
ASL Asti

Vernieri F; Altamura C; Brunelli N; Costa CM; Aurilia C; Egeo G; Fofi L; Favoni V; Pierangeli G; Lovati C; Aguggia M; d’Onofrio F; Doretti A; Di Fiore P; Finocchi C; Rao R; Bono F; Ranieri A; Albanese M; Cevoli S; Barbanti P; Capogrosso C; Bertuzzo D; Spitaleri D; Messina S; Trogu F; Frediani F; Baldi O; Di Cola FS; et alii...

GalcanezumAb for prevention of high frequency episodic and chronic migraine in the Real Life in ITaly: A multicenter prospective cohort study (the GARLIT study) in Cephalalgia

2021
ASL Asti

Vernieri F; Altamura C; Brunelli N; Costa CM; Aurilia C; Egeo G; Fofi L; Favoni V; Pierangeli G; Lovati C; Aguggia M; Bertuzzo D; D'Onofrio F; Doretti A; Di Fiore P; Frediani F; Finocchi C; Rao R; Schiano Di Cola F; Bono F; Ranieri A; Albanese M; Cevoli S; Barbanti P;

Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology / Neurol Sci. 2020 Dec;41(Suppl 2):487-488. doi: 10.1007/s10072-020-04669-y.

2020
ASL Asti

Vernieri F; Altamura C; Aurilia C; Brunelli N; Egeo G; Fofi L; Costa CM; Fallacara A; Favoni V; Pierangeli G; Aguggia M; Bertuzzo D; Albanese M; Di Fiore P; Frediani F; Cevoli S; Barbanti P;